You Are Here:
Clinical Summary of U.S. Preventive Services Task Force Recommendation
This document is a summary of the 2009 recommendation of the U.S. Preventive Services Task Force (USPSTF) on aspirin for the prevention of cardiovascular disease. This summary is intended for use by primary care clinicians.
Select for copyright and source information.
Age 45-79 Years
Age 55-79 Years
Age <45 Years
Age <55 Years
|Men & Women
Age ≥80 Years
|Recommendation||Encourage aspirin use when potential CVD benefit (MIs prevented) outweighs potential harm of GI hemorrhage.||Encourage aspirin use when potential CVD benefit (strokes prevented) outweighs potential harm of GI hemorrhage.||Do not encourage aspirin use for MI prevention.||Do not encourage aspirin use for stroke prevention.||No Recommendation|
|Grade: A||Grade: D||Grade: I
|How to Use This Recommendation||
|Relevant Recommendations from the USPSTF||
Abbreviations: CHD = coronary heart disease, CVD = cardiovascular disease, GI = gastrointestinal, HDL = high-density lipoprotein, MI = myocardial infarction, NSAIDs = nonsteroidal anti-inflammatory drugs.
For the full recommendation statement and supporting documents, please go to: http://www.uspreventiveservicestaskforce.org.
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Copyright and Source Information
This document is in the public domain within the United States.
Requests for linking or to incorporate content in electronic resources should be sent via the USPSTF contact form.
AHRQ Publication No. 09-05129-EF-3
Current as of March 2009
U.S. Preventive Services Task Force. Aspirin for the Prevention of Cardiovascular Disease: Clinical Summary. AHRQ Publication No.09-05129-EF-3, March 2009. http://www.uspreventiveservicestaskforce.org/uspstf09/aspirincvd/aspcvdsum.htm